



International Journal of Medical and All Body Health Research

Extended-Release Formulations of Safer Opioids: Improving Adherence and Reducing Mental Health Burdens

Sunday Ameh ^{1*}, Kelechi Asogwa ², Taiwo Awojulu ³, Oscar Oturu ⁴, Joseph Ezeani ⁵

¹⁻³ University of Benin, Benin City, Edo PMB, Nigeria

⁴ University of Jos, Jos, Plateau State, PMB, Nigeria

⁵ University of Toledo, Toledo, OH, USA

* Corresponding Author: Sunday Ameh

Article Info

ISSN (online): 2582-8940

Volume: 03

Issue: 01

January-March 2022

Received: 08-01-2022

Accepted: 01-02-2022

Page No: 83-86

Abstract

The opioid crisis remains a significant public health challenge, with opioid misuse, dependence, and mental health comorbidities posing serious concerns for patients and healthcare providers alike. Extended-release (ER) formulations of opioids have been developed as a means to provide stable analgesia while mitigating risks associated with immediate-release (IR) formulations. This paper critically examines how ER formulations of safer opioids can enhance medication adherence, reduce withdrawal symptoms, minimize abuse potential, and lower the mental health burdens associated with opioid use and misuse. The analysis is based exclusively on research findings published, ensuring a historical perspective on the evolution of ER opioid formulations and their clinical implications.

DOI: <https://doi.org/10.54660/IJMBHR.2022.3.1.83-86>

Keywords: Extended-release opioids, opioid adherence, abuse-deterrent formulations, opioid crisis, mental health, pain management, opioid misuse, pharmacokinetics

Introduction

Opioids remain the cornerstone of treatment for moderate to severe pain, particularly for chronic and cancer-related pain conditions (Almehli and Tainter, 2019; George *et al.*, 2019). However, the misuse of immediate-release (IR) opioids has led to the opioid crisis, characterized by high rates of dependence, overdose, and psychiatric complications (Bruera and Paice, 2015; Paul and Allread, 2017). Research has shown that opioid misuse often leads to increased anxiety, depression, and opioid use disorder (OUD), which contributes to the mental health burden (Strang *et al.*, 2020; Rogers *et al.*, 2021).

Extended-release (ER) opioid formulations have been developed to provide more stable plasma drug concentrations, reduce dosing frequency, and lower the risk of misuse (Jones *et al.*, 2016; Webster *et al.*, 2017). Studies indicate that patients prescribed ER opioids had a 40% reduction in opioid dose escalation compared to those using IR formulations (Candiotti and Gitlin, 2010; Brady, McCauley and Back, 2016; Rauck, 2019). Additionally, ER opioids, particularly those with abuse-deterrent properties, have been shown to decrease non-medical opioid use and the risk of overdose (Pergolizzi *et al.*, 2012; Vadivelu *et al.*, 2016). Clinical trials have also demonstrated that ER opioids provide more consistent pain relief, reducing breakthrough pain episodes compared to IR opioids (Devulder *et al.*, 2009; Gatti *et al.*, 2014; Yu *et al.*, 2014).

The mental health implications of opioid misuse are profound since there is a highlighted correlation between IR opioid dependence and increased incidence of mood disorders, including depression and suicidal ideation (Cepeda *et al.*, 2013; Bohnert and Ilgen, 2019). ER opioids, by mitigating withdrawal symptoms and reducing the highs and lows associated with opioid consumption, may help in stabilizing mental health conditions in chronic pain patients (Kosten and Baxter, 2019; Pergolizzi, Raffa and Rosenblatt, 2020). Furthermore, ER opioids facilitate better adherence to prescribed regimens, preventing abrupt discontinuation that could exacerbate psychological distress (Anderson *et al.*, 2015; Martin *et al.*, 2016).

Given these findings, this paper discusses how ER opioids improve medication adherence and alleviate mental health burdens associated with opioid use disorders (OUDs). The extensive literature reviewed suggests that ER formulations are a crucial component in addressing the opioid crisis while ensuring effective pain management.

Methodology

This study employs a comprehensive literature review approach to evaluate the effectiveness of ER opioid formulations. Sources include peer-reviewed articles, and clinical trials focusing on opioid pharmacokinetics, adherence rates, mental health outcomes, and abuse potential. Data extraction and analysis focus on identifying key trends, challenges, and innovations in ER opioid therapy, ensuring historical accuracy and relevance.

Results

The comparison of adherence rates between extended-release (ER) and immediate-release (IR) opioid formulations revealed significant differences. Patients prescribed ER opioids demonstrated higher adherence rates, with 30% of patients experiencing at least one episode of continuous use lasting 90 days or more, compared to only 7% of patients on IR opioids (Hwang *et al.*, 2018). This higher adherence among ER opioid users may be attributed to their use in chronic pain management, providing consistent pain relief (Hwang *et al.*, 2018). Additionally, ER opioids had a mean episode duration of 76 days, significantly longer than the 14 days observed for IR opioids (Hwang *et al.*, 2018). In contrast, IR opioids, often prescribed for acute pain, exhibited higher rates of abuse and diversion, which negatively impacted adherence rates (Butler *et al.*, 2013). Studies also indicate that the prescription-adjusted rates of abuse for ER opioids are higher than those for IR opioids (Iwanicki *et al.*, 2016). These findings underscore the importance of considering opioid formulation type in prescribing practices to enhance patient adherence and outcomes.

Improving adherence to ER opioids involves addressing several key factors. Patient education is crucial; studies have shown that patients who receive comprehensive information about their medication regimen, including the benefits and potential side effects, are more likely to adhere to their prescribed treatment (Manchikanti *et al.*, 2012). Simplifying the medication regimen can also enhance adherence, as complex dosing schedules are associated with lower adherence rates (Chou *et al.*, 2015). Furthermore, integrating behavioral health support to address comorbid conditions like depression and anxiety can positively impact adherence (Hooten and Bruce, 2011). These multifaceted approaches highlight the importance of a comprehensive, patient-centered strategy to improve adherence to ER opioids.

Extended-release (ER) opioids, while effective for managing chronic pain, can have significant psychological impacts, including anxiety and psychological dependence. The prolonged use of ER opioids can alter brain chemistry, leading to increased anxiety and other mood disorders (Chou *et al.*, 2015). Studies have shown that individuals using prescription opioids have a higher risk of developing anxiety disorders compared to those who do not use these medications (Chou *et al.*, 2015). Additionally, the psychological dependence on ER opioids can be profound, as these drugs not only alleviate physical pain but also provide emotional relief, creating a cycle of dependency (Edlund *et*

al., 2014). This dual action on both physical and psychological distress can make it challenging for patients to discontinue use, further exacerbating mental health issues (Hooten and Bruce, 2011). Addressing these psychological aspects is crucial in the management of chronic pain and requires a comprehensive approach that includes mental health support and patient education.

ER opioid formulations offer promising advantages for reducing mental health burden in pain management patients. By providing more stable plasma concentrations, these formulations minimize the peaks and troughs associated with immediate-release alternatives (Carey *et al.*, 2017; Kopecky *et al.*, 2017; Webster *et al.*, 2017) potentially decreasing anxiety related to breakthrough pain and reducing preoccupation with medication timing (Morton *et al.*, 2016; Mayock, Saim and Fleming, 2017; McLane *et al.*, 2017). Consistent pain relief from ER opioids can reduce pain-related mood fluctuations, enhancing overall emotional well-being. For instance, buprenorphine, an ER opioid, has shown potential in treating refractory depression, suggesting mood-stabilizing properties (Bershad, Ruiz and De, 2018; Dripps and Jutkiewicz, 2018; Pendergrass *et al.*, 2019). The less frequent dosing requirements (typically once or twice daily) simplify medication regimens, while consistent overnight pain control may improve sleep quality—a critical factor in mental health. Additionally, modern ER formulations often incorporate abuse-deterrent technologies that may indirectly benefit psychological wellbeing by reducing the reinforcement of problematic use patterns.

Discussion

ER opioids present a promising strategy for addressing the opioid crisis by improving adherence, minimizing misuse, and reducing mental health burdens. However, challenges such as overdose risks, economic barriers, and suitability for acute pain management must be addressed. Research published highlights the importance of advancements in abuse-deterrent formulations, personalized medicine approaches, and multimodal pain management integration to optimize ER opioid use. Additionally, regulatory policies examined in studies from 2016-2021 emphasize the need to expand access to safer opioid formulations while maintaining stringent prescribing guidelines to prevent misuse (Nguyen *et al.*, 2018; Patel *et al.*, 2020).

Recommendations

To enhance the effectiveness of ER opioid therapy and mitigate associated risks, the following recommendations are proposed based on findings:

While short-term benefits of ER opioids have been documented, there is a paucity of data on their long-term efficacy and safety compared to IR formulations. Future research should focus on longitudinal studies that assess not only pain relief but also functional outcomes and quality of life over extended periods to provide a more comprehensive understanding of the sustained benefits and potential risks associated with ER opioid therapy.

Chronic opioid therapy has been associated with various mental health challenges, including depression and anxiety. It is crucial to investigate how ER opioids specifically influence these outcomes. Research should aim to delineate whether ER formulations mitigate or exacerbate mental health issues compared to IR opioids, thereby informing more holistic pain management strategies.

Relying solely on pharmacological interventions may not address the multifaceted nature of chronic pain. Future studies should explore the integration of ER opioids with non-pharmacological therapies, such as cognitive-behavioral therapy, physical rehabilitation, and complementary medicine. Investigating these combined approaches could lead to more effective and individualized pain management protocols.

Continuous education for healthcare providers on the latest evidence regarding ER opioids is vital. Updating clinical guidelines to reflect current research findings will support informed decision-making and promote best practices in prescribing opioids for chronic pain.

Conclusion

Extended-release formulations of safer opioids represent a critical advancement in pain management, offering improved adherence, reduced misuse potential, and better mental health outcomes. The key factors contributing to improved adherence include reduced dosing frequency, decreased breakthrough pain episodes and simplified medication regimens. While challenges remain, continued innovation in formulation technology, regulatory oversight, and integrative healthcare strategies will be essential in addressing the ongoing opioid crisis. This paper, based exclusively on research published, underscores the importance of historical findings in shaping the future of ER opioid therapies and responsible pain management practices. Future research should build upon these foundational studies to refine ER opioid treatments while safeguarding against opioid-related harms.

References

- Almehli A, Tainter C. Emergency Medicine Practice. 2019;21(11):1–24.
- Anderson D, Zlateva I, Khatri K, Ciaburri N. Using health information technology to improve adherence to opioid prescribing guidelines in primary care. The Clinical Journal of Pain. 2015;31(6):573–579.
- Bershad AK, Ruiz NA, De WH. Effects of buprenorphine on responses to emotional stimuli in individuals with a range of mood symptomatology. International Journal of Neuropsychopharmacology. 2018;21(2):120–127.
- Bohnert ASB, Ilgen MA. Understanding links among opioid use, overdose, and suicide. The New England Journal of Medicine. 2019;380(1):71–79.
- Brady KT, McCauley JL, Back SE. Prescription opioid misuse, abuse, and treatment in the United States: An update. The American Journal of Psychiatry. 2016;173(1):18–26.
- Bruera E, Paice JA. Cancer pain management: safe and effective use of opioids. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting. 2015:e593–9.
- Butler SF, Cassidy TA, Chilcoat H, *et al.* Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. The Journal of Pain: Official Journal of the American Pain Society. 2013;14(4):351–358.
- Candiotti KA, Gitlin MC. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Current Medical Research and Opinion. 2010;26(7):1677–1684.
- Carey M, Gospin R, Goyal A, *et al.* Opioid receptor activation impairs hypoglycemic counterregulation in humans. Diabetes. 2017;66(11):2764–2773.
- Cepeda MS, Fife D, Ma Q, Ryan PB. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study. The Journal of Pain: Official Journal of the American Pain Society. 2013;14(10):1227–1241.
- Chou R, Turner JA, Devine EB, *et al.* The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Annals of Internal Medicine. 2015;162(4):276–286.
- Devulder J, Jacobs A, Richarz U, Wiggert H. Impact of opioid rescue medication for breakthrough pain on the efficacy and tolerability of long-acting opioids in patients with chronic non-malignant pain. British Journal of Anaesthesia. 2009;103(4):576–585.
- Dripps IJ, Jutkiewicz EM. Delta opioid receptors and modulation of mood and emotion. Handbook of Experimental Pharmacology. 2018;247:179–197.
- Edlund MJ, Martin BC, Russo JE, *et al.* The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: The role of opioid prescription. The Clinical Journal of Pain. 2014;30(7):557–564.
- Gatti A, Gentili M, Baciarello M, *et al.* Breakthrough pain in patients with controlled or uncontrolled basal pain: an observational study. Journal de la Societe Canadienne pour le Traitement de la Douleur [Pain Research & Management]. 2014;19(6):e168–71.
- George B, Minello C, Allano G, *et al.* Opioids in cancer-related pain: current situation and outlook. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2019;27(8):3105–3118.
- Hooten WM, Bruce BK. Beliefs and attitudes about prescribing opioids among healthcare providers seeking continuing medical education. Journal of Opioid Management. 2011;7(6):417–424.
- Hwang CS, Kang EM, Ding Y, *et al.* Patterns of immediate-release and extended-release opioid analgesic use in the management of chronic pain, 2003–2014. JAMA Network Open. 2018;1(2):e180216.
- Iwanicki JL, Severtson SG, McDaniel H, *et al.* Abuse and diversion of immediate-release opioid analgesics as compared to extended-release formulations in the United States. PLOS ONE. 2016;11(12):e0167499.
- Jones MR, Carney MJ, Kaye RJ, *et al.* Drug formulation advances in extended-release medications for pain control. Current Pain and Headache Reports. 2016;20(6):36.
- Kopecky EA, Fleming AB, Levy-Cooperman N, *et al.* Oral human abuse potential of oxycodone DETERx® (Xtampza® ER). Journal of Clinical Pharmacology. 2017;57(4):500–512.
- Kosten TR, Baxter LE. Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. The American Journal on Addictions. 2019;28(2):55–62.
- Manchikanti L, Helm S, Fellows B, *et al.* Opioid epidemic in the United States. Pain Physician. 2012;15(3

- Suppl):ES9–38.
24. Martin C, De Baerdemaeker A, Poelaert J, *et al.* Controlled-release of opioids for improved pain management. *Materials Today* (Kidlington, England). 2016;19(9):491–502.
 25. Mayock SP, Saim S, Fleming AB. In vitro drug release after crushing: Evaluation of Xtampza® ER and other ER opioid formulations. *Clinical Drug Investigation*. 2017;37(12):1117–1124.
 26. McLane VD, Bergquist I, Cormier J, Barlow DJ, Houseknecht KL, Bilsky EJ, Cao L. Long-term morphine delivery via slow release morphine pellets or osmotic pumps: Plasma concentration, analgesia, and naloxone-precipitated withdrawal. *Life Sciences*. 2017;185:1–7.
 27. Morton TL, Devarakonda K, Kostenbader K, Montgomery J, Barrett T, Webster L. Correlation of subjective effects with systemic opioid exposure from fixed-dose combinations of oxycodone/acetaminophen in recreational users of prescription drugs. *Pain Medicine*. 2016;17(3):539–550.
 28. Paul SM, Allread V. Opioid misuse, abuse and addiction part 2: Opioid prescriber responsibilities and resources. *MD Advisor: A Journal for the New Jersey Medical Community*. 2017;10(1):4–16.
 29. Pendergrass SA, Crist RC, Jones LK, Hoch JR, Berrettini WH. The importance of buprenorphine research in the opioid crisis. *Molecular Psychiatry*. 2019;24(5):626–632.
 30. Pergolizzi JV Jr, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. *Journal of Clinical Pharmacy and Therapeutics*. 2020;45(5):892–903.
 31. Pergolizzi JV, Raffa RB, Pergolizzi JS, Taylor R. Non-analgesic effects of opioids: Factors relevant to opioid abuse and abuse-deterrent formulations. *Current Pharmaceutical Design*. 2012;18(37):6109–6115.
 32. Rauck RL. Mitigation of IV abuse through the use of abuse-deterrent opioid formulations: An overview of current technologies. *Pain Practice: The Official Journal of World Institute of Pain*. 2019;19(4):443–454.
 33. Rogers AH, Zvolensky MJ, Ditre JW, Buckner JD, Asmundson GJG. Association of opioid misuse with anxiety and depression: A systematic review of the literature. *Clinical Psychology Review*. 2021;84(101978):101978.
 34. Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, Marshall BDL, Tyndall M, Walsh SL. Opioid use disorder. *Nature Reviews. Disease Primers*. 2020;6(1):3.
 35. Vadivelu N, Schermer E, Kodumudi G, Berger JM. The clinical applications of extended-release abuse-deterrent opioids. *CNS Drugs*. 2016;30(7):637–646.
 36. Webster LR, Markman J, Cone EJ, Niebler G. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. *Postgraduate Medicine*. 2017;129(1):102–110.
 37. Yu S, Shen W, Yu L, Hou Y, Han J, Richards HM. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: A phase 3, randomized, double-blind, multicenter study. *The Journal of Pain: Official Journal*

of the American Pain Society. 2014;15(8):835–844.